The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.
 
Martin McCarter
Research Funding - Merck
Other Relationship - Debbies Dream Foundation
 
Richard P. Tobin
No Relationships to Disclose
 
Dasha T. Cogswell
No Relationships to Disclose
 
Victoria M. Vorwald
No Relationships to Disclose
 
Dana Davis
No Relationships to Disclose
 
Robert J. Van Gulick
No Relationships to Disclose
 
Kasey L. Couts
No Relationships to Disclose
 
Kimberly R. Jordan
No Relationships to Disclose
 
Victoria Nuanes
No Relationships to Disclose
 
Dexiang Gao
No Relationships to Disclose
 
Theresa Michelle Medina
Consulting or Advisory Role - Bristol Meyer Squibb; Iovance Biotherapeutics
Research Funding - BioAtla (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Nektar (Inst); Replimune (Inst)
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; Regeneron; Roche; Sanofi
Research Funding - alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Rene Gonzalez
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Johnson & Johnson; Lilly; Merck; Novartis; Pfizer; Procter & Gamble; Sanofi
Consulting or Advisory Role - Amgen
Research Funding - Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exicure (Inst); Immunocore (Inst); Incyte (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); Moderna Therapeutics (Inst); Morphotek (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech; Senhwa Biosciences (Inst); Syndax (Inst); Synlogic (Inst); Taiga (Inst); Takeda (Inst); Tesaro (Inst); Ultimovacs (Inst)
 
Ross W. McFarland
No Relationships to Disclose
 
William A. Robinson
No Relationships to Disclose